Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

892
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
892
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

783
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
783
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

858
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
858
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

934
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
934
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Weight-loss practices and dietary quality in Chinese adolescents.

BMC public health·2026
Same author

Propofol-based versus volatile anesthesia and postoperative immune response in prostate cancer.

Translational andrology and urology·2026
Same author

Structural insights into flexible pyruvate binding in an (S)-selective ω-transaminase.

Biochemical and biophysical research communications·2026
Same author

Efficient whole-cell biocatalytic synthesis of 2'-deoxy-2'-fluoroadenosine, a key building block for nucleic acid drugs.

Synthetic and systems biotechnology·2026
Same author

The RNAi machinery regulates lovastatin biosynthesis via microRNA-like RNAs in industrial <i>Aspergillus terreus</i>.

Synthetic and systems biotechnology·2026
Same author

Corrigendum to "TCF7L2 transcriptionally regulates C1QB to exacerbate synaptic pruning-dependent neuronal injury in the epileptic hippocampus" [Brain Res. Bull. 235 (2026) 111730].

Brain research bulletin·2026
Same journal

A Ni-Mediated Cross-Coupling Approach to Deuterated <sup>18</sup>F- Fluoromethylated (Hetero)arenes.

Journal of the American Chemical Society·2026
Same journal

Efficient Light-Driven CO<sub>2</sub> Capture and Reversible Release Enabled by Metastable Photoacid-Decorated Metal-Organic Frameworks.

Journal of the American Chemical Society·2026
Same journal

In Situ Raman Spectroscopy Reveals the Dynamic Evolution and Ethanol Dependence of SEI Structure in Li-Mediated N<sub>2</sub> Reduction Reaction.

Journal of the American Chemical Society·2026
Same journal

Solvent Esterification and Stoichiometric Control in Ambient-Grown FAPbI<sub>3</sub> Single-Crystal Solar Cells.

Journal of the American Chemical Society·2026
Same journal

Unlocking Azulene Functionalization via Strain-Induced Azulyne Intermediates.

Journal of the American Chemical Society·2026
Same journal

An Oxazine-Locked Covalent Organic Framework by a Tandem Pinner/Schiff Base Reaction for Hydrogen Peroxide Photosynthesis.

Journal of the American Chemical Society·2026
查看所有相关文章

相关实验视频

Updated: Jul 27, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

氨酸A

Jinfeng Zhang1,2, Dandan Feng1,2, Jianjun Cheng1,2

  • 1iHuman Institute, ShanghaiTech University, Shanghai 201210, China.

Journal of the American Chemical Society
|June 5, 2023
PubMed
概括
此摘要是机器生成的。

-19核磁共振 (19F-NMR) 光谱为选G蛋白合受体 (GPCR) 配体提供了一种新方法. 使用新型探针分子的这种方法为发现向A2A腺受体 (A2AAR) 的新药候选提供了强大的替代方案.

更多相关视频

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

726

相关实验视频

Last Updated: Jul 27, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.6K
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

726

科学领域:

  • 医学化学
  • 生物物理
  • 药理学

背景情况:

  • 传统上,G蛋白结合受体 (GPCR) 配体结合亲和力是使用放射性配体竞争试验来测量的.
  • 19F核磁共振 (19F-NMR) 光谱是一种新兴的小分子化合物查技术.
  • 现有的测量连体结合亲和度和选化合物的方法通常涉及不同的实验条件.

研究的目的:

  • 开发和验证含的探针分子FPPA,用于与A2A腺受体 (A2AAR) 的结合研究.
  • 为药物查和 afinity 测量建立一个强大的 1D 19F-NMR 协议.
  • 证明 19F-NMR 与 FPPA 在发现新型 A2AAR 向药物的有用性.

主要方法:

  • 基于A2AAR-V-2006复合物的含探头分子 (FPPA) 的结构设计.
  • 对1D 19F-NMR测量的实验条件的开发.
  • 使用已知的A2AAR配体验证基于FPPA的19F-NMR协议.

主要成果:

  • 一种含的新型探针分子FPPA成功设计用于A2AAR结合研究.
  • 使用FPPA进行了验证的1D 19F-NMR方案,用于药物查和亲和度测量.
  • 该方法在识别已知的A2AAR配体方面表现出强大.

结论:

  • 使用FPPA探针的19F-NMR光谱是一种可行的,强大的替代方法,用于A2AAR连接体的发现.
  • 这种方法促进了候选药物的选,并扩大了潜在的A2AAR向治疗方法的库.
  • 这种方法对发现具有新型核心结构的配体具有前景.